News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UK’s NICE Rejects GlaxoSmithKline, Genmab A/S Leukemia Drug, Arzerra
June 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark's Genmab, has been rejected by Britain's cost watchdog NICE in preliminary draft guidance.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
Tariffs
Trump Tarries on Tariffs Again, Delays Plans by Weeks: Report
August 14, 2025
·
2 min read
·
Tristan Manalac
PODCAST
The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know
August 14, 2025
·
1 min read
·
Lori Ellis
Podcast
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
August 13, 2025
·
2 min read
·
Heather McKenzie
